Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM42ENF)

• Drug Name: IPRONIAZIDE Drug Info
• Synonyms: iproniazid; 54-92-2; N'-Isopropylisonicotinohydrazide; Iprazid; Marsilid; Iproniazide; Euphozid; Rivivol; Marsalid; Yatrozide; 4-Pyridinecarboxylic acid, 2-(1-methylethyl)hydrazide; Iproniazyd [Polish]; Propilniazida; Ipronid; Ro 2-4572; N'-Isopropylisonicotinoylhydrazide; Iproniazide [INN-French]; Iproniazidum [INN-Latin]; UNII-D892HFI3XA; Iproniazida [INN-Spanish]; 1-Isonicotinoyl-2-isopropylhydrazine; N'-isopropylpyridine-4-carbohydrazide; CCRIS 9177; C9H13N3O; P 887; EINECS 200-218-8; Isonicotinic acid 2-isopropylhydrazide; BRN 0

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3748
  ChEBI ID: CHEBI:5958
  CAS Number: CAS 54-92-2
  TTD Drug ID: DM42ENF

Molecule-Related Drug Atlas

Drug(s) Targeting Monoamine oxidase type B (MAO-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[3]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[4]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[5]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[6]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[7]
Rasagiline	DM3WKQ4	Parkinson disease	8A00.0	Approved	[8]
Sulphadoxine	DMZI2UF	Malaria	1F40-1F45	Approved	[9]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[10]
Indeloxazine	DMWO3N6	Dementia	6D80-6D86	Approved	[11]
Budipine	DMODHQI	Migraine	8A80	Approved	[12]

Drug(s) Targeting Monoamine oxidase type A (MAO-A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[13]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[14]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[15]
Isocarboxazid	DMAF1NB	Depression	6A70-6A7Z	Approved	[16]
TRYPTAMINE	DMAFPHB	N. A.	N. A.	Phase 3	[17]
Psoralen	DMIZJ8M	N. A.	N. A.	Phase 3	[18]
CHF-3381	DMQ2O8V	Neuropathic pain	8E43.0	Phase 2	[19]
Ladostigil	DMJSY3Q	Alzheimer disease	8A20	Phase 2	[20]
CX157	DMS2WB5	Mood disorder	6A60-6E23	Phase 2	[21]
PIPERINE	DMYEAB1	Vitiligo	ED63.0	Phase 1/2	[22]

Drug(s) Affected By Proepiregulin (EREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[23]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[2]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[24]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[2]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[2]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[25]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[26]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[27]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[28]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[2]

Drug(s) Affected By Antileukoproteinase (SLPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[2]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[2]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[24]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[2]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[2]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[2]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[2]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[29]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[2]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[2]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[30]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[31]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[2]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[2]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[2]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[32]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[26]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[2]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[33]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[32]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[34]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[35]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[36]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[37]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[38]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[39]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[2]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[40]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[41]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[2]

Drug(s) Affected By Bone morphogenetic protein 6 (BMP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[2]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[2]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[42]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[2]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[2]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[2]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[2]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[43]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[2]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[44]

Drug(s) Affected By Interleukin-24 (IL24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[45]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[2]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[39]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[2]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[2]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[46]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[27]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[47]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[2]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[47]

Drug(s) Affected By PTB-containing, cubilin and LRP1-interacting protein (PID1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[2]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[2]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[2]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[2]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[2]
Amikacin	DM5PDRB	Bacteremia	1A73	Approved	[2]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[2]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[2]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[2]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[48]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[1]
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[2]
Bone morphogenetic protein 6 (BMP6)	OT9WN536	BMP6_HUMAN	Gene/Protein Processing	[2]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Gene/Protein Processing	[2]
Interleukin-24 (IL24)	OT4VUWH1	IL24_HUMAN	Gene/Protein Processing	[2]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[2]
Proepiregulin (EREG)	OTRM4NQY	EREG_HUMAN	Gene/Protein Processing	[2]
PTB-containing, cubilin and LRP1-interacting protein (PID1)	OT5YJ7FI	PCLI1_HUMAN	Gene/Protein Processing	[2]

References

• [1] Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64.
• [2] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [3] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [4] Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
• [5] Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
• [7] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [8] Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
• [9] Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
• [10] Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [12] Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
• [13] Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
• [14] Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
• [15] Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
• [16] MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
• [17] Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
• [18] Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
• [19] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [20] Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
• [21] Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
• [22] Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
• [23] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [24] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [25] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [26] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [27] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [28] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [29] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [30] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [31] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [32] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [33] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [34] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [35] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [36] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [37] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [38] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [39] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [40] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [41] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [42] Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci. 2007 Mar;34(3):310-23. doi: 10.1016/j.mcn.2006.11.008. Epub 2006 Dec 28.
• [43] 2,3,7,8-tetrachlorodibenzo-p-dioxin augments the modulation of gene expression mediated by the thyroid hormone receptor. Toxicol Appl Pharmacol. 2004 Feb 1;194(3):201-10. doi: 10.1016/j.taap.2003.09.010.
• [44] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [45] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [46] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [47] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [48] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.